Filing Details

Accession Number:
0001181431-11-058857
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-12-05 19:50:07
Reporting Period:
2011-12-05
Filing Date:
2011-12-05
Accepted Time:
2011-12-05 19:50:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178711 Transcept Pharmaceuticals Inc TSPT Pharmaceutical Preparations (2834) 330960223
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1454351 N Nikhilesh Singh C/O Transcept Pharmaceuticals, Inc.
1003 W. Cutting Blvd, Suite 110
Point Richmond CA 94804
Svp & Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2011-12-05 13,237 $7.59 1,554 No 4 S Direct
Common Stock Disposition 2011-12-05 36,709 $7.59 0 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 295 Indirect See footnote
Common Stock 78,206 Indirect See footnote
Footnotes
  1. Shares held directly by the Nikhilesh and Nikki Singh Revocable Trust (the "Revocable Trust") for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by the Revocable Trust except to the extent of his pecuniary interest therein.
  2. Shares held directly by the Reporting Person's spouse.
  3. Shares held directly by the Singh Family Trust (the "Family Trust") for which Reporting Person's spouse serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by the Family Trust except to the extent of his pecuniary interest therein.
  4. The sales price reported in column 4 of Table 1 represents the weighted average sales price of the shares sold within an estimated range from $8.16 to $7.20 per share. Upon request of the commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.